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LETTERS TO THE EDITOR
Cytokines and Acute Cardiac Rejection--the
Unfulffied Promise?
The interesting report of Fyfe et al . (1) on coronary sinus sampling
of cytokines after heart transplantation is based on the hypothesis
that if cytokines were being actively produced within the graft, there
should be a significant difference between cytokine concentration
measured from the coronary sinus and that obtained during simul-
taneous sampling from the superior vena cava, The current theory
on the sequence of immune recognition of a foreign antigen, its
pwwrw,ttion to the T lymphocyte receptor and subsequent activa-
tion of lymphocytes proposes a process driven by various cytokines
stimulating the invasion of cytotoxic T cells into the graft and the
inflammatory changes seen on endomyocardial biopsy (2,3) . We and
others (4,5) have previously reported a temporal relation between
the sequences of elevated soluble interleukin-2 receptor levels and
subsequent significant cardiac allograft rejection spanning a number
of days, We suggest that the peak levels of immune activators may
either predate the histologic changes or relate to the early develop-
ment of rejection . It is therefore not surprising that Fyfe et al . (1)
were unable to demonstrate any direct correlation between concur-
rent cytokine levels and biopsy grade .
Their secondary hypothesis regarding the measurement of cyto-
kine concentration in the coronary sinus or superior vena cava or
the difference between these two concentrations and its correlation
with the severity of rejection on myocardial biopsy any be similarly
flawed. Furthermore, the investigators give no breakdown of the
various rejection grades obtained. Were higher levels noted in the
higher rejection grades? This would be hard to interpret given the small
sample
SIZe .
Fyfe et al, give no indication of how they deemed cytokine
activity to be "baseline" when they compared cytokine concentra-
tions measured during the absence of rejection with those measured
during an episode of rejection in each patient . There is a striking
augmentation of cytokine release after acute tissue injury due to a
surgical procedure, as well as after bacterial and viral infection (0) ;
if blood specimens are taken during this time, the sampling will be
invalidated and the levels of cytokines potentially very high . The
harvesting of endomyocardial biopsy tissue as part of a routine
surveillance endomyocardial biopsy that shows acute rejection may
not reflect the level of cytokine activation that may have been
present well before the detection of an abnormality on routine
surveillance endomyocardial biopsy . The peak levels of various
immune markers may well predate the histologic changes or relate to
the early development of rejection and could therefore explain the
poor relation between simultaneous interleukin-2 receptor levels
and allograft rejection (2,4) . The rejection process itself may have
been present for some time before biopsy, when cytokine activation
may have been at its highest ; at the time of taking the blood samples
the rejection process may even he in a state of resolution, or
cytokine production in a state of exhaustion . The histologic changes
seen at the time of acute rejection, although specific, probably are a
relatively late reflection of immune activation .
The recent development of various immune specific monoclonal
antibodies (7,8) provides great help in the interpretation of the role
of cytokines and offers exciting alternatives to the current immuno-
suppressive armamentarium for the treatment of significant rejec-
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tion. The approach of Fyfe et al . (1) potentially creates unjustified
prejudice against these agents, and we suggest that the utility of
cytokine monitoring in solid organ transplantation requires serial
collection of samples, with detailed reference to the level of immu-
nosuppression, tissue injury and so forth, taking place in the weeks
preceding sampling to best interpret levels .
STEPHEN H. JENNISON, BSc, MRCP, FOP
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Reply
The points raised by Jennison et al . are interesting and I think
adequately covered in our discussion . Our hypothesis that coronary
sinus cytokine levels represent a cardiac source are subject to the
caveats mentioned in our report and not by Jennison et al . : 1)
penetration from the interstitial space ; 2) coronary blood flow
(known to be increased in heart transplant patients both at baseline
and especially during rejection [I]) ; and 3) clearance of the cytokine
from the serum . Interleukin-2 (IL-2) receptors, which appear to be
the major focus of the letter of Jennison et al ., have a relatively long
half-life in serum, which may make it impossible to detect differ-
ences between the coronary sinus and superior vena cava . In our
cases, as explained in the Discussion . IL-2 receptor levels were
artificially elevated by antithymocyte preparations, which may have
obscured any potential differences .
The suggestion of Jennison et al . that cytokine release predates
rejection is shown in our Figure 7 . Similar profiles were seen for
interleukin-4 and tumor necrosis factor-alpha. What length of time
should we allow to elapse before we consider a particular cytokine
release to be associated with a specific rejection episode? Only
careful collection of multiple samples over time will allow this
question to be answered . We cannot ethically justify performing this
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